{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:25:52Z","timestamp":1780334752965,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.drudis.2021.04.006","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T06:41:24Z","timestamp":1618555284000},"page":"2214-2220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The fight against COVID-19: Striking a balance in the renin\u2013angiotensin system"],"prefix":"10.1016","volume":"26","author":[{"given":"Alexis Q.","family":"Dean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne D.","family":"Twomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancy","family":"Nalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.04.006_b0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.04.006_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110231","article-title":"COVID-19 and the renin\u2013angiotensin system (RAS): a spark that sets the forest alight?","volume":"144","author":"Wiese","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.drudis.2021.04.006_b0015","doi-asserted-by":"crossref","DOI":"10.1007\/s42399-020-00363-4","article-title":"Comorbidity and its impact on patients with COVID-19","author":"Sanyaolu","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.drudis.2021.04.006_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2021.04.006_b0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.drudis.2021.04.006_b0035","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3201\/eid2609.202095","article-title":"Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States","volume":"26","author":"Martines","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.drudis.2021.04.006_b0040","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2021.04.006_b0045","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.006_b0050","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/HYPERTENSIONAHA.106.084848","article-title":"Angiotensin-1-7 counterregulates angiotensin II signaling in human endothelial cells","volume":"50","author":"Sampaio","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2021.04.006_b0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.drudis.2021.04.006_b0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0065","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","article-title":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS","volume":"39","author":"Oudit","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.drudis.2021.04.006_b0075","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.dsx.2020.06.064","article-title":"Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events","volume":"14","author":"Nandy","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.drudis.2021.04.006_b0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd873","article-title":"Drugs targeting the renin-angiotensin-aldosterone system","volume":"1","author":"Zaman","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2021.04.006_b0085","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.drudis.2021.04.006_b0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients","volume":"22","author":"Baral","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.drudis.2021.04.006_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.559841","article-title":"Insights on SARS-CoV-2 molecular interactions with the renin\u2013angiotensin system","volume":"8","author":"Costa","year":"2020","journal-title":"Front Cell. Dev. Biol."},{"key":"10.1016\/j.drudis.2021.04.006_b0100","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.04.006_b0105","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.04.006_b0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.04.006_b0115","article-title":"SARS-CoV-2 uses clathrin-mediated endocytosis to gain access into cells","volume":"296","author":"Bayati","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.006_b0120","doi-asserted-by":"crossref","unstructured":"R. Amraie, M.A. Napoleon, W. Yin, J. Berrigan, E. Suder, G. Zhao, et al., CD209L\/L-SIGN and CD209\/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells, bioRxiv 2020; 2020.06.22.165803","DOI":"10.1101\/2020.06.22.165803"},{"key":"10.1016\/j.drudis.2021.04.006_b0125","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10157-018-1567-1","article-title":"Independent regulation of renin-angiotensin-aldosterone system in the kidney","volume":"22","author":"Nishiyama","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.drudis.2021.04.006_b0130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/me.2004-0536","article-title":"Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II","volume":"20","author":"Hunyady","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.drudis.2021.04.006_b0135","doi-asserted-by":"crossref","first-page":"H736","DOI":"10.1152\/ajpheart.00937.2006","article-title":"Prevention of angiotensin II-induced cardiac remodeling by angiotensin-1-7","volume":"292","author":"Grobe","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.drudis.2021.04.006_b0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.006_b0145","doi-asserted-by":"crossref","unstructured":"R.A. Santos, A.C. Simoes e Silva, C. Maric, D.M. Silva, R.P. Machado, I. de Buhr, et al., Angiotensin-1-7; is an endogenous ligand for the G protein-coupled receptor Mas, Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 8258\u201363","DOI":"10.1073\/pnas.1432869100"},{"issue":"1_Suppl.","key":"10.1016\/j.drudis.2021.04.006_b0150","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1177\/14703203010020013001","article-title":"Review: Intrarenal angiotensin II levels in normal and hypertensive states","volume":"2","author":"Navar","year":"2001","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.drudis.2021.04.006_b0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/hh0901.089882","article-title":"Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function","volume":"88","author":"Serneri","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2021.04.006_b0160","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1159\/000450564","article-title":"Overexpression of intrarenal renin-angiotensin system in human acute tubular necrosis","volume":"41","author":"Cao","year":"2016","journal-title":"Kidney Blood Press Res."},{"key":"10.1016\/j.drudis.2021.04.006_b0165","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.04.006_b0170","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.drudis.2021.04.006_b0175","doi-asserted-by":"crossref","unstructured":"N. Liu, Y. Hong, R.-G. Chen, H.-M. Zhu , High rate of increased level of plasma angiotensin II and its gender difference in COVID-19: an analysis of 55 hospitalized patients with COVID-19 in a single hospital, WuHan, China, medRxiv 2020; 2020.2004.2027.20080432","DOI":"10.21203\/rs.3.rs-51770\/v1"},{"key":"10.1016\/j.drudis.2021.04.006_b0180","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-020-03015-0","article-title":"Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients","volume":"24","author":"Wu","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.drudis.2021.04.006_b0200","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20209610","article-title":"The protein expression profile of ACE2 in human tissues","volume":"16","author":"Hikmet","year":"2020","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.drudis.2021.04.006_b0205","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.cmi.2020.07.020","article-title":"Viable SARS-CoV-2 in various specimens from COVID-19 patients","volume":"26","author":"Jeong","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drudis.2021.04.006_b0210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiaa332","article-title":"ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19","volume":"222","author":"Pinto","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drudis.2021.04.006_b0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-2-19","article-title":"ACE2 gene expression is up-regulated in the human failing heart","volume":"2","author":"Goulter","year":"2004","journal-title":"BMC Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0220","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1440-1797.2011.01467.x","article-title":"Urinary angiotensin-converting enzyme 2 in patients with CKD","volume":"16","author":"Mizuiri","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.drudis.2021.04.006_b0225","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.mayocp.2020.04.028","article-title":"Marked up-regulation of ACE2 in hearts of patients with obstructive hypertrophic cardiomyopathy: implications for SARS-CoV-2-mediated COVID-19","volume":"95","author":"Bos","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drudis.2021.04.006_b0230","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.pan.2012.07.017","article-title":"Severe acute pancreatitis is associated with upregulation of the ACE2-angiotensin-1-7-Mas axis and promotes increased circulating angiotensin-1-7","volume":"12","author":"Wang","year":"2012","journal-title":"Pancreatology"},{"key":"10.1016\/j.drudis.2021.04.006_b0235","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/CS20130420","article-title":"Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421","volume":"127","author":"Lambert","year":"2014","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2021.04.006_b0240","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2021.04.006_b0245","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.006_b0250","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.04.006_b0255","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jinf.2020.06.060","article-title":"The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates","volume":"81","author":"Liang","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.drudis.2021.04.006_b0260","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID\u201319","volume":"16","author":"Kreutz","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2021.04.006_b0265","doi-asserted-by":"crossref","first-page":"H2166","DOI":"10.1152\/ajpheart.00061.2006","article-title":"Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats","volume":"291","author":"Jessup","year":"2006","journal-title":"Am. J. Physiol. Heart and Circulatory Physiol."},{"key":"10.1016\/j.drudis.2021.04.006_b0270","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.04.006_b0275","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.drudis.2021.04.006_b0280","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0285","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0290","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.04.006_b0295","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients","volume":"43","author":"Trifir\u00f2","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.drudis.2021.04.006_b0300","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.120.16314","article-title":"Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients","volume":"77","author":"Semenzato","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2021.04.006_b0305","doi-asserted-by":"crossref","unstructured":"R.D. Lopes, A.V.S. Macedo, P.G.M. de Barros E Silva, R.J. Moll-Bernardes, A. Feldman, G. D'Andr\u00e9a Saba Arruda, et al., Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--the BRACE CORONA Trial, Am. Heart J. 2020; 226, 49\u201359","DOI":"10.1016\/j.ahj.2020.05.002"},{"key":"10.1016\/j.drudis.2021.04.006_b0310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2021.04.006_b0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.drudis.2021.04.006_b0320","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.drudis.2021.04.006_b0325","first-page":"192","article-title":"Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection","volume":"4","author":"Karoyan","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.drudis.2021.04.006_b0330","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.04.006_b0335","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","article-title":"Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation","volume":"94","author":"Liu","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2021.04.006_b0340","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31728","article-title":"Covid-19 and liver cirrhosis: focus on the non-classical renin\u2013angiotensin system and implications for therapy","author":"Sansoe","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2021.04.006_b0345","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-1-7; or an angiotensin II receptor antagonist","volume":"225","author":"W\u00f6sten-van Asperen","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.drudis.2021.04.006_b0350","doi-asserted-by":"crossref","first-page":"488","DOI":"10.34172\/apb.2020.068","article-title":"Angiotensin 1\u20137: a novel strategy in COVID-19 treatment","volume":"10","author":"Imanpour","year":"2020","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.drudis.2021.04.006_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109721","article-title":"Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19","volume":"74","author":"Poduri","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.drudis.2021.04.006_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100733","article-title":"COVID-19 update: the race to therapeutic development","volume":"53","author":"Twomey","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drudis.2021.04.006_b0365","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fimmu.2020.01131","article-title":"Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation","volume":"11","author":"Cardone","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drudis.2021.04.006_b0370","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2021.04.006_b0375","doi-asserted-by":"crossref","first-page":"L631","DOI":"10.1152\/ajplung.90415.2008","article-title":"Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells","volume":"297","author":"Zhang","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.drudis.2021.04.006_b0380","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1042\/CS20130291","article-title":"Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress","volume":"126","author":"Clarke","year":"2014","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2021.04.006_b0385","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2014.06.008","article-title":"Angiotensin II-regulated microRNA 483\u20133p directly targets multiple components of the renin-angiotensin system","volume":"75","author":"Kemp","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.drudis.2021.04.006_b0390","doi-asserted-by":"crossref","first-page":"35466","DOI":"10.1074\/jbc.M111.277434","article-title":"Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor alpha-converting enzyme (TACE\/ADAM-17) activation in primary human monocytes","volume":"286","author":"Scott","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2021.04.006_b0395","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2353\/ajpath.2008.070762","article-title":"Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK\/p38 MAP kinase pathway","volume":"172","author":"Koka","year":"2008","journal-title":"Am. J. Pathol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621001926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621001926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:53:45Z","timestamp":1761224025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621001926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1359644621001926"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.04.006","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The fight against COVID-19: Striking a balance in the renin\u2013angiotensin system","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}